Long-Term Visual Outcome of Patients with Blau Syndrome
PURPOSE: To document the long-term visual outcomes in patients with Blau syndrome.
METHODS: A retrospective institutional cohort study was conducted, and 13 patients with genetically confirmed Blau syndrome were included. Demographic and clinical data were collected from standardised medical charts. Baseline was defined as the first detected uveitis and data were recorded onwards at intervals of 1, 3, 5, 10, 15 and 20 years.
RESULTS: Anterior uveitis was the most common classification at baseline (57.1%). Among patients with documented uveitis lasting 10 years or more, all of them developed panuveitis. Median logMAR visual acuity at baseline was 0 (range -0.5; 0.7), 0.19 (range 0; 1.5) at year 5, and 0.7 (range 0.1 - no perception of light) at year 20, as recorded in 13, 16, and 10 eyes, respectively. All patients received treatment with topical and oral steroids, and multiple systemic immunosuppressants including biologics. Disease control, defined as having cells <1+ in both eyes and using topical steroid eye drops less than twice daily, was achieved in 14.3% to 37.5% of patients at the different time points. Cataract surgery was performed in 12 eyes of 8 patients, 3 eyes of 3 patients necessitated glaucoma surgery, and 4 eyes of 4 patients required surgery for retinal detachment.
CONCLUSION: Uveitis associated with Blau syndrome commonly leads to severe, chronic panuveitis, requiring long-term systemic immunosuppression. Early diagnosis and timely initiation of biologics may prevent significant visual impairment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Ocular immunology and inflammation - (2024) vom: 05. Jan., Seite 1-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kreps, Elke O [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologic treatment |
|---|
| Anmerkungen: |
Date Revised 05.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/09273948.2023.2293922 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366713671 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366713671 | ||
| 003 | DE-627 | ||
| 005 | 20240108142446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2023.2293922 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM366713671 | ||
| 035 | |a (NLM)38180755 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kreps, Elke O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Visual Outcome of Patients with Blau Syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a PURPOSE: To document the long-term visual outcomes in patients with Blau syndrome | ||
| 520 | |a METHODS: A retrospective institutional cohort study was conducted, and 13 patients with genetically confirmed Blau syndrome were included. Demographic and clinical data were collected from standardised medical charts. Baseline was defined as the first detected uveitis and data were recorded onwards at intervals of 1, 3, 5, 10, 15 and 20 years | ||
| 520 | |a RESULTS: Anterior uveitis was the most common classification at baseline (57.1%). Among patients with documented uveitis lasting 10 years or more, all of them developed panuveitis. Median logMAR visual acuity at baseline was 0 (range -0.5; 0.7), 0.19 (range 0; 1.5) at year 5, and 0.7 (range 0.1 - no perception of light) at year 20, as recorded in 13, 16, and 10 eyes, respectively. All patients received treatment with topical and oral steroids, and multiple systemic immunosuppressants including biologics. Disease control, defined as having cells <1+ in both eyes and using topical steroid eye drops less than twice daily, was achieved in 14.3% to 37.5% of patients at the different time points. Cataract surgery was performed in 12 eyes of 8 patients, 3 eyes of 3 patients necessitated glaucoma surgery, and 4 eyes of 4 patients required surgery for retinal detachment | ||
| 520 | |a CONCLUSION: Uveitis associated with Blau syndrome commonly leads to severe, chronic panuveitis, requiring long-term systemic immunosuppression. Early diagnosis and timely initiation of biologics may prevent significant visual impairment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biologic treatment | |
| 650 | 4 | |a Blau syndrome | |
| 650 | 4 | |a Blau syndrome-associated uveitis | |
| 650 | 4 | |a longitudinal study | |
| 650 | 4 | |a panuveitis | |
| 700 | 1 | |a Al Julandani, Dalila |e verfasserin |4 aut | |
| 700 | 1 | |a Guly, Catherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Arostegui, Juan I |e verfasserin |4 aut | |
| 700 | 1 | |a Dick, Andrew D |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanan, Athimalaipet V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g (2024) vom: 05. Jan., Seite 1-5 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:01 |g pages:1-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2023.2293922 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 01 |h 1-5 | ||